Dostarlimab vs Sintilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline and partners
NCT04655976 · Phase 2/3 · active, not recruiting
Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.
Next expected readout: January 2027 · NCT06879717 (registry estimate)
Reported efficacy
Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)
Result source: NCT04655976
Sintilimab
Marketed by Innovent Biologics and partners
NCT03607539 · Phase 3 · completed
This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.
Next expected readout: November 2026 · NCT05429463 (registry estimate)
Reported efficacy
Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)
Result source: NCT03150875
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dostarlimab | Sintilimab |
|---|---|---|
| PFS, median | 4.4 vs 4.1vs DocetaxelNCT046559762 other results
| 8.9 vs 5+3.9 vs placeboNCT036075392 other results
|
| OS, median | 11.9 vs 11.3vs DocetaxelNCT046559763 other results
| 11.8 vs 8.3vs DocetaxelNCT03150875 |
| ORR | 18.7% vs 14.5%vs DocetaxelNCT046559762 other results
| 51.9% vs 29.8%+22.1 vs placeboNCT036075392 other results
|
| Duration of response, median | 8.3 vs 8.8vs DocetaxelNCT046559762 other results
| 6.0 vs 5.1+1 vs placeboNCT036299251 other result
|
PFS, median
- Dostarlimab
- 4.4 vs 4.1vs DocetaxelNCT04655976
2 other results
- 4.2 vs 4.1 NCT04655976
- 4.4 NCT03308942
- Sintilimab
- 8.9 vs 5+3.9 vs placeboNCT03607539
2 other results
- 5.5 vs 4.9 NCT03629925
- 4.3 vs 2.8 NCT03150875
OS, median
- Dostarlimab
- 11.9 vs 11.3vs DocetaxelNCT04655976
3 other results
- 11.8 vs 11.3 NCT04655976
- 11.9 NCT04655976
- 11.8 NCT04655976
- Sintilimab
- 11.8 vs 8.3vs DocetaxelNCT03150875
ORR
- Dostarlimab
- 18.7% vs 14.5%vs DocetaxelNCT04655976
2 other results
- 18.3% vs 14.5% NCT04655976
- 9.1% NCT03308942
- Sintilimab
- 51.9% vs 29.8%+22.1 vs placeboNCT03607539
2 other results
- 44.7% vs 35.4% NCT03629925
- 25.5% vs 2.2% NCT03150875
Duration of response, median
- Dostarlimab
- 8.3 vs 8.8vs DocetaxelNCT04655976
2 other results
- 7.1 vs 8.8 NCT04655976
- 21.5 NCT03308942
- Sintilimab
- 6.0 vs 5.1+1 vs placeboNCT03629925
1 other result
- 12.4 vs 4.1 NCT03150875
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dostarlimab: 3 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dostarlimab | Sintilimab |
|---|---|---|
| Dropout rate | 25.6%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results21.6%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | n/a: no completion milestoneb NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsn/a: no completion milestone NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results—Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | —b NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results— NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 — NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 33.8%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results42.7%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 58.3%Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 28.2%b NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results38.9% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 50.3% NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a anaemia 34.8% neutropenia 31.5% fatigue 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 2 more resultsanaemia 31.5% fatigue 29.8% diarrhoea 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 nausea 58.3% diarrhoea 50% fatigue 41.7% NCT03308942 · Phase 2 · registry result, not featured evidence · combination | b anaemia 74.1% (placebo 78.6%) neutrophil count decreased 71.1% (placebo 62.6%) white blood cell count decreased 67.7% (placebo 64.1%) NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsanaemia 33.3% decreased appetite 23.6% pyrexia 21.5% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 93.3% (placebo 90.4%) white blood cell count decreased 88.8% (placebo 86%) neutrophil count decreased 83.2% (placebo 82%) NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dostarlimab
show 1 more result
Sintilimab
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Sintilimab's landscape